AtriCure's Q2 Filing Shows Equity Shifts, European Presence
Ticker: ATRC · Form: 10-Q · Filed: Jul 30, 2025 · CIK: 1323885
Sentiment: mixed
Topics: Medical Devices, Quarterly Earnings, SEC Filing, Equity Changes, Surgical Instruments, Healthcare Sector, International Operations
Related Tickers: ATRC
TL;DR
AtriCure's latest 10-Q reveals ongoing capital adjustments, suggesting a dynamic financial strategy that investors should scrutinize for future growth indicators.
AI Summary
AtriCure, Inc. (ATRC) filed its 10-Q for the period ending June 30, 2025, indicating a continued focus on surgical and medical instruments. While specific revenue and net income figures are not provided in the excerpt, the filing details changes in equity components. For the six months ended June 30, 2025, Additional Paid-In Capital increased, reflecting potential capital raises or stock-based compensation. Retained Earnings also saw adjustments, which could indicate profitability or dividend policies. The company's Accumulated Other Comprehensive Income also changed, suggesting fluctuations in unrealized gains or losses. The filing also notes the company's operations in Europe, indicating an international market presence. The consistent adjustments across equity accounts for both the three and six-month periods ending June 30, 2025, and 2024, highlight ongoing financial activity and capital management. The company's business address remains 7555 Innovation Way, Mason, OH, reinforcing its operational base.
Why It Matters
This 10-Q provides a snapshot of AtriCure's financial health and capital structure, crucial for investors assessing the company's stability and growth potential in the competitive surgical and medical instruments market. Changes in Additional Paid-In Capital could signal investor confidence or dilution, directly impacting shareholder value. For employees, a stable capital structure suggests job security and potential for growth. Customers benefit from a financially sound company that can continue to innovate and supply critical medical devices. The company's European operations indicate its global reach, positioning it against international competitors like Medtronic and Johnson & Johnson.
Risk Assessment
Risk Level: medium — The provided excerpt lacks specific revenue, net income, or detailed operational risks, making a definitive risk assessment challenging. However, the continuous adjustments in equity accounts, particularly Additional Paid-In Capital and Retained Earnings, without context on their drivers (e.g., profitability, share issuance, or buybacks), introduce uncertainty. While not inherently negative, the absence of detailed financial performance metrics prevents a full understanding of the company's financial stability and potential vulnerabilities, warranting a 'medium' risk level.
Analyst Insight
Investors should delve deeper into AtriCure's full 10-Q to understand the specific drivers behind the equity changes and assess the company's profitability and cash flow. Look for detailed revenue breakdowns, net income figures, and management's discussion and analysis to gain a comprehensive view of its financial performance and future outlook before making any investment decisions.
Key Numbers
- 2025-06-30 — Reporting Period End Date (The period covered by this 10-Q filing.)
- 2025-07-30 — Filing Date (The date the 10-Q was officially filed with the SEC.)
- 0001323885 — Central Index Key (CIK) (Unique identifier for AtriCure, Inc. with the SEC.)
- 10-Q — Form Type (The type of SEC filing, indicating a quarterly report.)
- 3841 — SIC Code (Standard Industrial Classification for Surgical & Medical Instruments & Apparatus.)
- 513-755-4100 — Business Phone (Contact number for AtriCure, Inc.)
- 7555 Innovation Way — Business Street Address (Primary physical location of AtriCure, Inc.)
- Mason, OH — Business City and State (Geographic location of AtriCure, Inc.'s headquarters.)
- 45040 — Business Zip Code (Postal code for AtriCure, Inc.'s business address.)
- DE — State of Incorporation (AtriCure, Inc. is incorporated in Delaware.)
Key Players & Entities
- AtriCure, Inc. (company) — filer of the 10-Q
- Europe (location) — geographic segment of operations
- Mason, OH (location) — business address of AtriCure, Inc.
- 2025-06-30 (date) — end of the reporting period
- 2025-07-30 (date) — filing date of the 10-Q
- 0001323885 (regulator) — Central Index Key (CIK) for AtriCure, Inc.
- 7555 Innovation Way (location) — street address of AtriCure, Inc.
- Surgical & Medical Instruments & Apparatus (industry) — Standard Industrial Classification (SIC) for AtriCure, Inc.
- Delaware (location) — state of incorporation for AtriCure, Inc.
- Bloomberg (company) — publisher of this analysis
FAQ
What were AtriCure's key financial changes in the Q2 2025 10-Q?
AtriCure's Q2 2025 10-Q, filed on July 30, 2025, for the period ending June 30, 2025, showed adjustments in equity accounts including Additional Paid-In Capital, Retained Earnings, and Accumulated Other Comprehensive Income, indicating ongoing capital management.
Does AtriCure, Inc. operate internationally according to the 10-Q?
Yes, the 10-Q explicitly mentions 'srt:EuropeMember' in relation to the reporting period ending June 30, 2025, confirming AtriCure, Inc.'s operations and presence in Europe.
What is AtriCure's primary business according to its SIC code?
AtriCure, Inc.'s Standard Industrial Classification (SIC) code is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus,' indicating its core business in manufacturing and distributing medical devices.
When was AtriCure's 10-Q for Q2 2025 filed with the SEC?
AtriCure, Inc. filed its 10-Q for the second quarter of 2025 on July 30, 2025, covering the financial period that concluded on June 30, 2025.
Where is AtriCure, Inc. headquartered?
AtriCure, Inc. is headquartered at 7555 Innovation Way, Mason, OH 45040, as stated in the business address section of the 10-Q filing.
What is the significance of changes in Additional Paid-In Capital for AtriCure?
Changes in AtriCure's Additional Paid-In Capital, as seen in the 10-Q for the period ending June 30, 2025, can signify new equity issuances, stock-based compensation, or other capital transactions, impacting the company's capital structure and potential dilution for existing shareholders.
How did Retained Earnings change for AtriCure in the first half of 2025?
The 10-Q indicates adjustments to AtriCure's Retained Earnings for the six months ended June 30, 2025, which reflects the accumulation of net income (or losses) over time, less any dividends paid, providing insight into the company's profitability and dividend policy.
What is AtriCure's fiscal year end?
AtriCure, Inc.'s fiscal year ends on December 31, as specified in the 'FISCAL YEAR END: 1231' section of the 10-Q filing.
What is the CIK number for AtriCure, Inc.?
The Central Index Key (CIK) for AtriCure, Inc. is 0001323885, which is used by the SEC to identify the company's filings.
What does the 10-Q reveal about AtriCure's risk profile?
While the excerpt lacks specific risk factors, the continuous adjustments in equity accounts without detailed context on revenue or net income suggest a 'medium' risk level. Investors need to review the full filing for a comprehensive understanding of operational and financial risks.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 30, 2025 regarding AtriCure, Inc. (ATRC).